REGENERON PHARMACEUTICALS, INC. (REGN) /
The cash flow of REGENERON PHARMACEUTICALS, INC. over the past 10 years
Chart REGENERON PHARMACEUTICALS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, REGENERON PHARMACEUTICALS, INC.'s operating cash flow was $4.98B and its capital expenditures $898.4M, leaving free cash flow of $4.08B. Free cash flow was above zero in all 10 years shown. It ranged from $974M in fiscal 2016 to $6.53B in fiscal 2021. Capital expenditures were highest in fiscal 2025, at $898.4M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $4.98B | $898.4M | $4.08B |
| 2024ended Dec 31, 2024 | $4.42B | $755.9M | $3.66B |
| 2023ended Dec 31, 2023 | $4.59B | $718.6M | $3.88B |
| 2022ended Dec 31, 2022 | $5.01B | $590.1M | $4.42B |
| 2021ended Dec 31, 2021 | $7.08B | $551.9M | $6.53B |
| 2020ended Dec 31, 2020 | $2.62B | $614.6M | $2B |
| 2019ended Dec 31, 2019 | $2.43B | $429.6M | $2B |
| 2018ended Dec 31, 2018 | $2.2B | $383.1M | $1.81B |
| 2017ended Dec 31, 2017 | $1.31B | $272.6M | $1.03B |
| 2016ended Dec 31, 2016 | $1.49B | $511.9M | $974M |
Fiscal years as REGENERON PHARMACEUTICALS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on REGENERON PHARMACEUTICALS, INC.
- The revenue of REGENERON PHARMACEUTICALS, INC.
- The profitability of REGENERON PHARMACEUTICALS, INC.
- The debt of REGENERON PHARMACEUTICALS, INC.
- The dividends of REGENERON PHARMACEUTICALS, INC.
- All of REGENERON PHARMACEUTICALS, INC.'s financials, charted
Companies of a similar size
- UPSUNITED PARCEL SERVICE INC
- TRVTravelers Companies, Inc.
- EOGEOG RESOURCES, INC.
- MCOMoody’s Corporation
- CDNSCADENCE DESIGN SYSTEMS, INC.
Not investment advice. This page shows what REGENERON PHARMACEUTICALS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.